Anti-VEGF therapy in mRCC

Differences between Asian and non-Asian patients

Y. Wang, T. K. Choueiri, J. L. Lee, M. H. Tan, SunYoung Rha, S. A. North, C. K. Kollmannsberger, D. F. McDermott, D. Y.C. Heng

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

Original languageEnglish
Pages (from-to)1433-1437
Number of pages5
JournalBritish Journal of Cancer
Volume110
Issue number6
DOIs
Publication statusPublished - 2014 Mar 18

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Population
Poisons
Therapeutics
Disease-Free Survival
Cohort Studies
Retrospective Studies
Databases
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wang, Y., Choueiri, T. K., Lee, J. L., Tan, M. H., Rha, S., North, S. A., ... Heng, D. Y. C. (2014). Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients. British Journal of Cancer, 110(6), 1433-1437. https://doi.org/10.1038/bjc.2014.28
Wang, Y. ; Choueiri, T. K. ; Lee, J. L. ; Tan, M. H. ; Rha, SunYoung ; North, S. A. ; Kollmannsberger, C. K. ; McDermott, D. F. ; Heng, D. Y.C. / Anti-VEGF therapy in mRCC : Differences between Asian and non-Asian patients. In: British Journal of Cancer. 2014 ; Vol. 110, No. 6. pp. 1433-1437.
@article{6bcd50c03b2c44c8a12f081d5bcb04c3,
title = "Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients",
abstract = "Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55{\%} vs 61{\%} P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.",
author = "Y. Wang and Choueiri, {T. K.} and Lee, {J. L.} and Tan, {M. H.} and SunYoung Rha and North, {S. A.} and Kollmannsberger, {C. K.} and McDermott, {D. F.} and Heng, {D. Y.C.}",
year = "2014",
month = "3",
day = "18",
doi = "10.1038/bjc.2014.28",
language = "English",
volume = "110",
pages = "1433--1437",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

Wang, Y, Choueiri, TK, Lee, JL, Tan, MH, Rha, S, North, SA, Kollmannsberger, CK, McDermott, DF & Heng, DYC 2014, 'Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients', British Journal of Cancer, vol. 110, no. 6, pp. 1433-1437. https://doi.org/10.1038/bjc.2014.28

Anti-VEGF therapy in mRCC : Differences between Asian and non-Asian patients. / Wang, Y.; Choueiri, T. K.; Lee, J. L.; Tan, M. H.; Rha, SunYoung; North, S. A.; Kollmannsberger, C. K.; McDermott, D. F.; Heng, D. Y.C.

In: British Journal of Cancer, Vol. 110, No. 6, 18.03.2014, p. 1433-1437.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-VEGF therapy in mRCC

T2 - Differences between Asian and non-Asian patients

AU - Wang, Y.

AU - Choueiri, T. K.

AU - Lee, J. L.

AU - Tan, M. H.

AU - Rha, SunYoung

AU - North, S. A.

AU - Kollmannsberger, C. K.

AU - McDermott, D. F.

AU - Heng, D. Y.C.

PY - 2014/3/18

Y1 - 2014/3/18

N2 - Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

AB - Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

UR - http://www.scopus.com/inward/record.url?scp=84896494305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896494305&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.28

DO - 10.1038/bjc.2014.28

M3 - Article

VL - 110

SP - 1433

EP - 1437

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -